|
Diaceutics PLC on Tuesday said its momentum was ‘strong’ in its first half, and maintained its confidence in hitting full-year targets for 2025. The Belfast, Northern Ireland-based diagnostic testing company estimated that revenue rose 22% on a constant currency basis during the six months that ended June 30. This takes first-half revenue to about £14.6 million from £12.3 million the year prior, and reflects a three-year compound growth rate of 25% during the first half. Annual recurring revenue was about 16% higher, climbing to £16.4 million at June 30 from £14.2 million one year prior. ARR accounted for roughly 70% of total revenue in the first-half, Diaceutics said, up from 55% in 2024. Cash totalled £10.4 million at June 30, down from £12.7 million at December 31 but in line with guidance. Diaceutics said it remains debt-free. Heading into the second half, the firm anticipates £8.8 million in revenue based on its order book at June 30, which would be down slightly from £8.9 million on-year. This gives Diaceutics about 79% visibility on market consensus, compared to 71% visibility in 2024. ‘These metrics are in line with the board’s expectations at this point in the year, providing good levels of revenue visibility and confidence in profitability expectations as the company enters the historically stronger second half of the year,’ Diaceutics said. Company-cited analyst consensus estimates full-year revenue of £40 million and adjusted earnings before interest, tax, depreciation and amortisation of £7.0 million. In 2024, Diaceutics posted revenue of £32.2 million and adjusted Ebitda of £4.2 million. Also on Tuesday, Diaceutics said an unnamed customer had expanded the scope of an existing contract, which will now include an additional service called Signal Connect. This involves data signal alerts for healthcare professionals using ‘rare or novel biomarkers’ in clinical testing. This is part of the company’s PMx commercialisation solution, ‘which integrates multiple services into a single, multi-year engagement’, with the aim of improving laboratory testing. According to Diaceutics, PMx is ‘a third of the cost of traditional commercialisation’. Diaceutics shares were 3.9% higher at 132.00 pence on Tuesday afternoon in London. Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
